BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 19788446)

  • 1. IMP-3 expression in melanocytic lesions.
    Yu L; Xu H; Wasco MJ; Bourne PA; Ma L
    J Cutan Pathol; 2010 Mar; 37(3):316-22. PubMed ID: 19788446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP-3 is a novel progression marker in malignant melanoma.
    Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
    Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DEK expression in melanocytic lesions.
    Kappes F; Khodadoust MS; Yu L; Kim DS; Fullen DR; Markovitz DM; Ma L
    Hum Pathol; 2011 Jul; 42(7):932-8. PubMed ID: 21316078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.
    Kapur P; Selim MA; Roy LC; Yegappan M; Weinberg AG; Hoang MP
    Mod Pathol; 2005 Feb; 18(2):197-204. PubMed ID: 15467715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
    Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
    Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
    McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
    J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study.
    Garrido-Ruiz MC; Requena L; Ortiz P; Pérez-Gómez B; Alonso SR; Peralto JL
    Mod Pathol; 2010 Sep; 23(9):1215-24. PubMed ID: 20543820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma.
    Harris GR; Shea CR; Horenstein MG; Reed JA; Burchette JL; Prieto VG
    Am J Surg Pathol; 1999 Jul; 23(7):786-94. PubMed ID: 10403301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
    Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
    J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p-27 (kip1) in nevi and melanomas.
    Morgan MB; Cowper SE
    Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.